Medical Oncology

, Volume 11, Issue 2, pp 35–41 | Cite as

Update of results of autologous bone marrow transplantation in lymphoma

  • Philip J. Bierman


A substantial proportion of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma will fail to achieve a complete remission with initial chemotherapy or will relapse after attaining a complete remission. The results of conventional salvage chemotherapy regimens for these patients have been disappointing. This has led to the use of highdose therapy regimens which can be administered with the use of hematopoietic rescue (bone marrow transplantation). The use of bone marrow transplantation for patients with relapsed and refractory lymphoma has increased rapidly. Data from the North American Autologous Bone Marrow Transplant Registry indicate that approximately 40 % of autologous bone marrow transplants are being performed for patients with lymphoma. Several large series of transplantation for Hodgkin’s disease and non-Hodgkin’s lymphoma have been published in the last two years1-12. The results of these series vary widely due to differences in patient selection and pre-transplant prognostic factors. Differences in supportive care and preparative regimens prior to transplant may also account for the wide range of outcomes reported after transplantation. Although these differences make it impossible to compare results of one series with another, it is clear that a significant proportion of patients can achieve long term disease free survival following high dose therapy with marrow transplantation. It is also important, however, to note that this form of therapy can be associated with substantial morbidity and mortality. Transplant-related mortality exceeds 20 % in some series. However, greater experience, better patient selection, and advances in supportive care, such as hematopoietic growth factors, are allowing many institutions to perform transplantation with mortality rates under 5 %.

Key Words

Bone marrow transplantation lymphoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gulati S, Yahalom J, Acaba L, Reich L, Motzer R, Crown J, Toia M, Igarashi T, Lemoli R, Hanninen E, Doherty M. Treatment of patients with relapsed and resistant non-Hodgkin’s lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation.J Clin Oncol,10, 936 (1992).PubMedGoogle Scholar
  2. 2.
    Lazarus HM, Crilley P, Ciobanu N, Creger R J, Fox R M, Shina D C, Bulova S I, Gucalp R, Cooper B W, Topolsky D, Soegiarso W, Brodsky I. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.J Clin Oncol,10, 1682 (1992).PubMedGoogle Scholar
  3. 3.
    Chopra R, McMillan A K, Linch D C, Yuklea S, Taghipour G, Pearce K G, Patterson K G, Goldstone A H. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients.Blood,8, 1137 (1993).Google Scholar
  4. 4.
    Crump M, Smith A M, Brandwein J, Couture F, Sherret H, Sutton D M C, Scott JG, McCrae J, Murray C, Pantalony D, Sutcliffe S B, Keating A. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: Importance of disease status at transplant.J Clin Oncol,11, 704 (1993).PubMedGoogle Scholar
  5. 5.
    Yahalom J, Gulati S C, Toia M, Maslak P, McCarron E G, O’Brien J P, Portlock C S, Straus D J, Phillips J, Fuks Z. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin’s disease.J Clin Oncol,11, 1062 (1993).PubMedGoogle Scholar
  6. 6.
    Wheeler C, Strawderman M, Ayash L, Churchill W H, Bierer B E, EliasA, Gilliland D G, Antman K, Guinan E C, Eder J P, Weinstein H, Schwartz G, Ferrara J, Mazanet R, Rimm I J, Tepler I, McCarthy P, Mauch P, Ault K, Gaynes L, McCauley M, Schnipper L E, Antin J.Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin’s lymphoma with cyclophosphamide, carmustine, and etoposide.J Clin Oncol,11, 1085 (1993).PubMedGoogle Scholar
  7. 7.
    Weaver C H, Appelbaum FR, Petersen F B, Clift R, Singer J, Press O, Bensinger W, Bianco J, Martin P, Anasetti C, Badger C, Deeg J, Dony K, Hansen J A, Petersdorf E, Rowley S, Storb R, Sullivan K, Witherspoon R, Weiden P, Buckner C D. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.J Clin Oncol,11, 1329 (1993).PubMedGoogle Scholar
  8. 8.
    Vose J M, Anderson J R, Kessinger A, Bierman P J, Coccia P, Reed E C, Gordon B, Armitage J O. High-dose chemotherapy and autologous-hematopoietic stem-cell transplantation for aggressive non-Hodgkin’s lymphoma.J Clin Oncol,11, 1846 (1993).PubMedGoogle Scholar
  9. 9.
    Bierman P J, Bagin R G, Jagannath S, Vose JM, Spitzer G, Kessinger A, Dicke K A, Armitage J O. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: Long term follow-up in 128 patients.Ann Oncol,4, 767 (1993).PubMedGoogle Scholar
  10. 10.
    Anderson J E, Litzow M R, Appelbaum FR, Schoch G, Fisher L D, Buckner C D, Petersen F B, Crawford S W, Press O W, Sanders J E, Bensinger W I, Martin P J, Storb R, Sullivan K M, Hansen J A, Thomas E D. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: The 21-year Seattle experience.J Clin Oncol,11, 2342 (1993).PubMedGoogle Scholar
  11. 11.
    Rapoport A P, Rowe J M, Kouides P A, Duerst R A, Abboud C N, Liesveld J L, Packman C H, Eberly S, Sherman M, Tanner M A, Constine L S, DiPersio J F. One hundred autotransplants for relapsed or refractory Hodgkin’s disease and lymphoma: Value of pretransplant disease status for predicting outcome.J Clin Oncol,11, 2351 (1993).PubMedGoogle Scholar
  12. 12.
    Reece D R, Connors J M, Spinelli J J, Barnett M J, Fairey R N, Klingemann H-G, Nantel S H, O#x2019;Reilly S, Shepherd J D, Sutherland H J, Voss N, Chann K-W, Phillips G L. Intensive therapy with cyclophosphamide, carmustine, etoposide + cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy.Blood,83, 1193 (1994).PubMedGoogle Scholar
  13. 13.
    Philip T, Armitage J O, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone A H, Gorin N C, Flesh M, Laporte JP, Maraninchi D, Pico J, Bosly A, Anderson C, Schots R,Biron P, Cabanillas F, Dicke K. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma.N Engl J Med,316, 1493 (1987).PubMedGoogle Scholar
  14. 14.
    Gribben J G, Goldstone A H, Linch D C, Taghipour G, McMillan A K, Souhami R L, Earl H, Richards J D M. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin’s lymphomas who are still responsive to conventional-dose therapy.J Clin Oncol,7, 1621 (1989).PubMedGoogle Scholar
  15. 15.
    Colombat P, Gorin N-C, Lemonnier MP, Binet C, Laporte J-P, Douay L, Desbois I, Lopez M, Lamagnere J-P, Najman A. The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin’s lymphoma.J Clin Oncol,8, 630 (1990).PubMedGoogle Scholar
  16. 16.
    Weisdorf D J, Haake R, Miller W J, McGlave P B, LeBien T W, Vallera D A, Lasky L C, Kim T H, Peterson B A, Ramsay N K C, Kersey J H, Hurd D D. Autologous bone marrow transplantation for progressive non-Hodgkin’s lymphoma: clinical impact of immunophenotype andin vitro purging.Bone Marrow Transplant,8, 135 (1991).PubMedGoogle Scholar
  17. 17.
    Takvorian T, Canellos G P, Ritz J, Freedman A S, Anderson K C, Mauch P, Tarbell N, Coral F, Daley H, Yeap B, Schlossman S F, Nadler L M. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin’s lymphoma with a poor prognosis.NEngl JMed,316, 1499 (1987).Google Scholar
  18. 18.
    Petersen F B, Appelbaum F R, Hill R, Fisher L D, Bigelow C L, Sanders J E, Sullivan K M, Bensinger W 1, Witherspoon R P, Storb R, Clift R A, Fefer A, Press O W, Weiden P L. Singer J, Thomas E D, Buckner C D. Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle.J Clin Oncol,8, 638 (1990).PubMedGoogle Scholar
  19. 19.
    Vose J M, Peterson C, Bierman P J, Weisenburger D D, Linder J, Harrington D, Vaughan W P, Kessinger A, Armitage J O. Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin’s lymphomas.Blood,76, 424 (1990).PubMedGoogle Scholar
  20. 20.
    Jones R J, Ambinder R F, Piantadosi S, Santos G W. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation.Blood,77, 649 (1991).PubMedGoogle Scholar
  21. 21.
    Chopra R, Goldstone A.H, Pearce R, Philip T, Petersen F, Appelbaum F, De Vol E, Ernst P. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Registry data.J Clin Oncol 11, 1690 (1992).Google Scholar
  22. 22.
    Shpall E J, Jones R B. Release of tumor cells from bone marrow.Blood,83, 623 (1994).PubMedGoogle Scholar
  23. 23.
    Vose J M, Bierman P J, Anderson J R, Kessinger A, Pierson J, Coccia P, Gordon B, Reed E C, Armitage J O. high-dose chemotherapy with hematopoietic stem cell rescue for non-Hodgkin’s lymphoma (NHL): Evaluation of event-free survival based on histologic subtype and rescue product.Proc Amer Soc Clin Oncol,11, 318 (1992).Google Scholar
  24. 24.
    Liberti G, Pearce R, Taghipour G, Majolino I, Goldstone A H. Comparison of peripheral and bone marrow autologous transplantation for lymphoma patients: a case controlled analysis of the EBMT Registry data.Fifth International Conference on Malignant Lymphoma (Lugano) p. 39, Abst #37 (1993)Google Scholar
  25. 25.
    Weisdorf D, Daniels K, Miller W, Blazar B, Perry E, Ramsay N, McGlave P, Kersey J. Bone marrow vs. peripheral blood stem cells for autologous lymphoma transplantation: A prospective randomized trial.Blood,82, 444a (1993).Google Scholar
  26. 26.
    Bierman P, Vose J, Anderson J, Bishop M, Pierson J, Armitage J, Kessinger A. Comparison of autologous bone marrow transplantaffon (ABMT) with peripheral stem cell transplantation (PSCT) for patients with Hodgkin’s disease (HD).Blood,82, 445a (1993).Google Scholar
  27. 27.
    Bosly A, Coiffier B, Gisselbrecht C, Tilly H, Auzanneau G, Andrien F, Herbrecht R, Legros M, Devaux Y, Jaubert J, Pignon B, Michaux J-L,Humblet Y, Dupriez B, Thyss A, Lederlin P. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen.J Clin Oncol,10, 1615 (1992).PubMedGoogle Scholar
  28. 28.
    Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, Spitzer G, Velasquez W, Weisenburger DD, Fernandez-Ranada J, SomersR, Rizzoli V, Harousseau J L, Sotto J J, Cahn JY Guilhot F, Biggs J, Sonneveld P, Misset J L,Manna A, Jagannath S, Guglielmi C, Chevreau C, Delmer A, Santini G, Coiffier B. Parma International protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation.Blood,77, 1587 (1991).PubMedGoogle Scholar
  29. 29.
    Zinzani P L, Tura S, Mazza M, Bocchia M, Gherlinzoni F, Pileri S, Amadori S, Martelli M, Guglielmi C, Papa G, Antimi M, Martelli M F, Liberati A M, Falini B, Calabresi F, Ruggeri EM, Dammacco F, Lauta V M, Lucarelli G, Moretti L, Mandelli F. ABMTvs. DHAP in residual disease following third generation regimens for aggressive non-Hodgkin’s lymphomas Fifth International Conference on Malignant Lymphoma, (Lugano) p.41, abst #41 (1993).Google Scholar
  30. 30.
    Hagenbeek A, Verdonck L, Sonneveld P, Schouten H, van ImhoffG, van PuttenW. CHOP chemotherapy versus autologous bone marrow transplantation in slowly responding patients with intermediate and high-grade malignant non-Hodgkin’s lymphoma. Results from a prospective randomized phase III clinical trial in 294 patients.Blood,10, 332a (1993).Google Scholar
  31. 31.
    Reece D E, Connors J M, Spinelli J J, Barnett M J, Fairey R N, Klingemann H-G, Nantel S H, O’Reilly S, Shepherd J D, Sutherland H J, Voss N, Chan K-W, Phillips G L. Intensive therapy with cyclophosphamide, carmustine, etoposide + cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy.Blood,83, 1193 (1994).PubMedGoogle Scholar
  32. 32.
    Viviani S, Santoro A, Negretti E, Bonfante V, Valagussa P, Bonadonna G: Salvage chemotherapy in Hodgkin’s disease.Ann Oncol,1, 123 (1990).PubMedGoogle Scholar
  33. 33.
    Bierman P, Anderson J, Vose J, Freeman M, Bishop M, Kessinger A, Armitage J. High-dose chemotherapy with autologous hematopoietic rescue for Hodgkin’s disease (HD) following first relapse after chemotherapy.Proc Am Soc Clin Oncol,12, 366 (1993).Google Scholar
  34. 34.
    Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Vaughan Hudson G. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomized trial.Lancet,341, 1051 (1993).PubMedCrossRefGoogle Scholar
  35. 35.
    Moreau P, Milpied N, Mechinaud-Lacroix F, Mahe B, Rapp M-J, Tortorec S L, Bourdin S, Dupas B, Harousseau J-L. Early intensive therapy wtih autotransplantation for high-risk Hodgkin’s disease.Leuk Lymphoma,12, 51 (1993).PubMedCrossRefGoogle Scholar
  36. 36.
    Gulati SC, Shank B, Black P, Yopp J, Koziner B, Straus D, Filippa D, Kempin S, CastroMalaspina H, Cunningham I, Berman E, Coleman M, Langleben A, Colvin O M, Fuks Z, O’Reilly R, Clarkson B. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma.J Clin Oncol 6, 1303 (1988).PubMedGoogle Scholar
  37. 37.
    Santini G, Coser P, Chisesi T, Porcellini A, Sertoli R, Contu A, Congiu A M, Manna A, Rossi E, Scarpati D, Rizzoli V. Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. A pilot study of the non-Hodgkin’s Lymphoma Co-operative Study Group (NHLCSG).Bone Marrow Transplant,4, 399 (1989).PubMedGoogle Scholar
  38. 38.
    Verdonck L F, Dekker A W, de Gast G C, Lokhorst H M, Nieuwenhuis HK. Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission.J Clin Oncol,10, 644 (1992).PubMedGoogle Scholar
  39. 39.
    Nademanee A, Schmidt G M, O’Donnell M R, Snyder D S, Parker P A, Stein A, Smith E, Lipsett J A, Sniecinski I, Margolin K, Somlo G, Niland J C, Blume K G, Forman S J. High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: A pilot study.Blood,80, 1130 (1992).PubMedGoogle Scholar
  40. 40.
    Freedman A S, Takvorian T, Neuberg D, Mauch P, Rabinowe S N, Anderson K C, Soiffer R J, Spector N, Grossbard M, Robertson M J, Blake K, Coral F, CaneIlos G P, Ritz J, Nadler L M. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkln’s lymphoma in first remission: A pilot study.J Clin Oncol,11, 931 (1993).PubMedGoogle Scholar
  41. 41.
    Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Bosly A, Tilly H, Morel P, Nouvel C, Herbrecht R, D’Agay M F, Gaulard Ph, Reyes F. Comparison of autologous bone marrow transplantation (ABMT) with sequential chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL) in first complete remission: A study on 464 patients (LNH87 Protocol).Blood,82, 87a (1993).Google Scholar
  42. 42.
    Carella A M, Carlier P, Congiu A, Occhini D, Nati S, Santini G, Pierluigi D, Giordano D, Bacigalupo A, Damasio E. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin’s disease in first compete remission after MOPP/ABVD protocol.Bone Marrow Transplant,8, 99 (1991).PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1994

Authors and Affiliations

  • Philip J. Bierman
    • 1
  1. 1.University of Nebraska Medical CenterDepartment of Internal Medicine Section of Oncology/HematologyOmahaUSA

Personalised recommendations